

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported)**  
August 5, 2025

---

**Twist Bioscience Corporation**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38720**  
(Commission  
File Number)

**46-2058888**  
(I. R. S. Employer  
Identification No.)

**681 Gateway Boulevard**  
**South San Francisco, CA 94080**  
(Address of principal executive offices, including ZIP code)

**(800) 719-0671**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TWST	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---



**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Appointment of Trynka Shineman Blake to the Board of Directors*

On August 5, 2025, the Board of Directors (the “Board”) of Twist Bioscience Corporation (the “Company”) elected Trynka Shineman Blake to the Board, effective immediately. Ms. Shineman Blake will serve as a Class II director until her term expires at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) and, if elected at the Annual Meeting, until her successor has been duly elected and qualified. Ms. Shineman Blake has been appointed to serve as a member of the Audit Committee of the Board.

In connection with her service as a director, Ms. Shineman Blake will receive the Company’s standard non-employee director cash and equity compensation, which includes (i) the \$50,000 annual cash retainer for her service as a director, (ii) the \$10,000 annual retainer for her service as a member of the Audit Committee of the Board, (iii) an initial equity award of restricted stock units with a grant date fair value of \$395,000, and (iv) an annual grant of restricted stock units with a grant date value equal to \$240,000 at the next annual meeting of stockholders.

There are no arrangements or understandings between Ms. Shineman Blake and any other persons pursuant to which she was selected as a director. Ms. Shineman Blake has no family relationships with any of the Company’s directors or executive officers and she has not been involved in any transactions that require disclosure pursuant to Item 404(a) of Regulation S-K.

On August 6, 2025, the Company issued a press release announcing the election of Ms. Shineman Blake to the Board, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press release dated August 6, 2025 titled “Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors”</a>
104	Cover Page Interactive Data File (formatted as Inline XBRL)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 6, 2025

**Twist Bioscience Corporation**

/s/ Judy Yan

Judy Yan

Assistant General Counsel and Assistant Secretary



## **Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors**

SOUTH SAN FRANCISCO, Calif., – August 6, 2025 – Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpres company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing.

"Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Her expertise in accelerating product development and optimizing customer experience in both e-commerce and traditional marketing environments aligns with our growth strategy, and her focus on the customer fits seamlessly with our customer-centric culture and mission. As a seasoned Board member, her guidance will be beneficial as we enter our next phase of growth."

"Twist's position at the intersection of advanced technology and biology coupled with diverse markets provides a myriad of opportunities for growth," said Ms. Shineman Blake. "I look forward to sharing my insight and contributing to the company's strategic direction during this critical inflection point as Twist advances toward adjusted EBITDA breakeven while continuing to deliver innovative solutions."

Ms. Shineman Blake previously served as CEO of Vistaprint (a division of Cimpres) focused on building a better way for microbusinesses to promote themselves. Prior to her tenure as CEO of Vistaprint, she held various positions of increasing responsibility at Vistaprint, including president of North America, executive vice president of global marketing and chief customer officer. During her tenure at Vistaprint, Ms. Shineman Blake played a pivotal role in scaling the business from under \$100 million to more than \$1 billion in revenue. She aligned the organization under a customer-centric culture, led a comprehensive re-architecture of the company's technology platform to accelerate the pace of product launches and nurtured an innovation portfolio that expanded Vistaprint's offerings into new markets and services. Before Vistaprint, she held senior positions at PreVision Marketing, a boutique analytic and marketing agency (acquired by Valassis). Ms. Shineman Blake serves on the boards of several public and private companies, including Tripadvisor, Semrush, Captura, a Charlesbank company, and Steer. She previously served on the boards of Ally Financial Inc. and UBM, PLC; the Management Board of Vistaprint (Cimpres) and the Board of Trustees for the Mass Technology Leadership Council. Ms. Shineman Blake holds a B.A. in psychology from Cornell University and an M.B.A. from Columbia Business School.

### **About Twist Bioscience Corporation**

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture and industrial chemicals, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.



Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit [www.twistbioscience.com](http://www.twistbioscience.com).

Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

### **Twist Bioscience Legal Notice Regarding Forward-Looking Statements**

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding growth of Twist's business. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

### **CONTACTS:**

#### **For Investors:**

Angela Bitting SVP, Corporate Affairs 925-202-6211  
[abitting@twistbioscience.com](mailto:abitting@twistbioscience.com)

#### **For Media:**

Amanda Houlihan Communications Manager 774-265-5334  
[ahoulihan@twistbioscience.com](mailto:ahoulihan@twistbioscience.com)

###